Introduction
Hydralazine-induced lupus syndrome (HILS) was first reported in 1953. 1 The syndrome occurs in 5-10% of patients taking hydralazine, presenting with arthralgia, myalgia, fever and serositis. Severe cardiac involvement is rare, and only three cases of tamponade were reported. [1] [2] [3] We describe an unusual case of impending cardiac tamponade in a patient taking hydralazine and coumadin.
Case presentation
A 68-year-old female presented with exertional dyspnea and pleuritic chest pain of 1 week duration.
The pain was increased by recumbancy and deep inspiration, and relieved by leaning forward. Associated symptoms included low grade fever but no joint pain or rash. She had paroxysmal atrial fibrillation on coumadin, and hypertension treated with hydralazine 100 mg three times daily for years.
Physical examination revealed a blood pressure of 140/80 with 10 mmHg paradox, sinus tachycardia of 115 bpm, respiratory rate of 20 per minute and normal body temperature. The jugular venous pressure was elevated at 10 cm, and heart sounds were faint with no pericardial rub. Labs revealed anemia (hemoglobin of 6.7 g/dl), with normal white and platelet counts. International normalized ratio (INR) was supratherapeutic at 6.8 (ref, 0.8-1.2). Twelvelead EKG showed sinus tachycardia, low voltage QRS complexes ( Figure 1A ). Transthoracic echocardiogram revealed a large circumferential pericardial effusion ( Figure 1B and C) with features of impending tamponade and respirophasic variation in the mitral and tricuspid valves of 31 and 50%, respectively. There was no diastolic collapse, but inferior vena cava was dilated at 2.3 cm. Transfusion of fresh frozen plasma was started, and the patient underwent surgical subxiphoid pericardial window. The fluid was hemorrhagic in nature with negative infectious and malignancy workup. Pathology showed evidence of organizing fibrinous exudate, consistent with chronic pericarditis. Erythrocyte sedimentation ! The Author 2013. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com rate was 105 mm/h and C-reactive protein was 11.7 mg/dl. Serologies revealed anti-nuclear antibody (ANA) of 11.5 OD ratio (normal < 1.5 OD ratio), antichromatin antibodies 1.7 AI (normal < 1.0) and antihistone antibodies 5.4 U (normal < 1.0). A diagnosis of HILS was established, and patient was started on high-dose prednisone after stopping hydralazine. She made an excellent recovery with resolution of effusion on repeat echocardiograms.
Discussion
HILS commonly presents with arthritis, myalgia, fever and constitutional symptoms. The incidence is dose dependent; with 10.4% of patients on 200 mg of hydralazine develop it after 3 years treatment in slow acetylator patients. 4 Following the publication of A-HeFT trial, there has been an increase in the amount of hydralazine prescribed to patients with heart failure. Although the total daily dose of hydralazine used in A-HeFT was just above 200 mg daily, there is good evidence to suggest that these patients and those receiving lower doses are not free from the risk of development of HILS. 5 Pericarditis occurs infrequently in HILS (<5%) as compared to 20% in the spontaneously occurring systemic lupus erythematosis. Anti-histone antibodies, a distinctive marker for druginduced lupus, and ANA are present in >95 % of the syndrome. 6 Discontinuation of drug inducing lupus is a critical part in the management. Corticosteroids and immunosuppressive therapies are only required in life-threatening cases of HILS. 6 A timely diagnosis is needed in critical organ illnesses, and further diagnostic testing is underscored as early treatment is mandatory. 5 In conclusion, we present a life-threatening case of HILS in a patient on coumadin, which required timely diagnosis and urgent treatment. 
